Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets
Research output: Contribution to journal › Review › Research › peer-review
Standard
Glial Cells in Glaucoma : Friends, Foes, and Potential Therapeutic Targets. / García-Bermúdez, Mariana Y.; Freude, Kristine K.; Mouhammad, Zaynab A.; van Wijngaarden, Peter; Martin, Keith K.; Kolko, Miriam.
In: Frontiers in Neurology, Vol. 12, 624983, 2021.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glial Cells in Glaucoma
T2 - Friends, Foes, and Potential Therapeutic Targets
AU - García-Bermúdez, Mariana Y.
AU - Freude, Kristine K.
AU - Mouhammad, Zaynab A.
AU - van Wijngaarden, Peter
AU - Martin, Keith K.
AU - Kolko, Miriam
PY - 2021
Y1 - 2021
N2 - Glaucoma is the second leading cause of blindness worldwide, affecting ~80 million people by 2020 (1, 2). The condition is characterized by a progressive loss of retinal ganglion cells (RGCs) and their axons accompanied by visual field loss. The underlying pathophysiology of glaucoma remains elusive. Glaucoma is recognized as a multifactorial disease, and lowering intraocular pressure (IOP) is the only treatment that has been shown to slow the progression of the condition. However, a significant number of glaucoma patients continue to go blind despite intraocular pressure-lowering treatment (2). Thus, the need for alternative treatment strategies is indisputable. Accumulating evidence suggests that glial cells play a significant role in supporting RGC function and that glial dysfunction may contribute to optic nerve disease. Here, we review recent advances in understanding the role of glial cells in the pathophysiology of glaucoma. A particular focus is on the dynamic and essential interactions between glial cells and RGCs and potential therapeutic approaches to glaucoma by targeting glial cells.
AB - Glaucoma is the second leading cause of blindness worldwide, affecting ~80 million people by 2020 (1, 2). The condition is characterized by a progressive loss of retinal ganglion cells (RGCs) and their axons accompanied by visual field loss. The underlying pathophysiology of glaucoma remains elusive. Glaucoma is recognized as a multifactorial disease, and lowering intraocular pressure (IOP) is the only treatment that has been shown to slow the progression of the condition. However, a significant number of glaucoma patients continue to go blind despite intraocular pressure-lowering treatment (2). Thus, the need for alternative treatment strategies is indisputable. Accumulating evidence suggests that glial cells play a significant role in supporting RGC function and that glial dysfunction may contribute to optic nerve disease. Here, we review recent advances in understanding the role of glial cells in the pathophysiology of glaucoma. A particular focus is on the dynamic and essential interactions between glial cells and RGCs and potential therapeutic approaches to glaucoma by targeting glial cells.
KW - astrocytes
KW - Glaucoma
KW - glia
KW - microglia
KW - Müller glial cells
KW - oligodendrocytes
KW - retinal ganglion cells
KW - retinal glia interactions
U2 - 10.3389/fneur.2021.624983
DO - 10.3389/fneur.2021.624983
M3 - Review
C2 - 33796062
AN - SCOPUS:85103405633
VL - 12
JO - Frontiers in Neurology
JF - Frontiers in Neurology
SN - 1664-2295
M1 - 624983
ER -
ID: 259777187